”We are excited to welcome Dr. Aaron Waxman to our Board of Directors,” said David Scheer, Chairman of the Board of Directors at OrphAI. “His clinical leadership will be an important contribution to ...

A multi-omics study reveals that impaired branched-chain amino acid (BCAA) catabolism is a key driver of sarcopenia, ...

In frame translation initiation sites within coding sequences drive the expression of N-terminally truncated proteoforms.

Today’s burning question from Cochlear's (ASX:COH) poorly received interim results is whether users are on a buyer’s strike ahead of upgraded implants and processors – or whether the problems are more ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

Aubrey de Grey had a large mouse study of combinations of antiaging treatments. They did show that combination treatments did ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...

Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...

In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of ...

Palvella Therapeutics is set to expand its 24-week Phase III SELVA trial to include subjects aged three to five years old for ...